Biopharmaceuticals
ABVC BioPharma Receives Additional $100,000 Payment from OncoX, Strengthening Licensing Revenue Strategy
ABVC BioPharma's continued licensing payments from OncoX BioPharma demonstrate the successful execution of its asset-light business model and highlight the growing value of plant-based cancer therapies in the biopharmaceutical market.
ABVC BioPharma Reports $1.28 Million in Q3 Licensing Revenue, Strengthening High-Margin Business Model
ABVC BioPharma has collected $1.28 million in Q3 licensing revenues from multiple partners, including OncoX BioPharma, demonstrating the profitability of its licensing framework with minimal incremental costs.
Creative Biolabs Advances Biopharmaceutical Innovation Through Glycobiology Expertise
Creative Biolabs is enhancing biopharmaceutical development through advanced glycoprotein engineering and polysaccharide analysis technologies that improve drug efficacy, safety, and stability.
Quantum BioPharma Ltd. Seeks Shareholder Approval for $600K Private Placement
Quantum BioPharma Ltd. is seeking shareholder approval for a $600,000 private placement to fund general working capital, highlighting the company's ongoing efforts to advance its biopharmaceutical innovations.
AAA Biotech Expands Recombinant Proteins Portfolio to Advance Life Sciences Research
AAA Biotech enhances its recombinant proteins portfolio, offering high-quality research reagents to support groundbreaking biomedical research.
ABVC BioPharma Secures $2.5 Million in International Investments to Fuel Growth
ABVC BioPharma's recent $2.5 million investment from international backers underscores confidence in its innovative therapies and strategic direction, marking a significant step forward in its clinical and commercial endeavors.
Nutriband Inc. Ties Shareholder Rewards to FDA Approval Milestone with 25% Preferred Stock Dividend
Nutriband Inc. (NASDAQ: NTRB) has announced a 25% preferred stock dividend, linking shareholder rewards directly to the FDA approval process for its lead product, AVERSA(TM) Fentanyl, highlighting the significance of regulatory achievements in biopharmaceutical value creation.
OncoX and ABVC BioPharma Strengthen Collaboration to Advance Oncology Treatments
OncoX BioPharma's deepened alliance with ABVC BioPharma signifies a strategic move to enhance its oncology pipeline, leveraging ABVC's IND-stage programs to develop innovative cancer therapies.
Quantum BioPharma Ltd. Acquires GameStop Shares in Strategic Move Against Market Manipulation
Quantum BioPharma Ltd. has purchased GameStop shares as part of its campaign against market corruption, highlighting its commitment to combating manipulative trading practices while advancing its biopharmaceutical research.
Creative Biolabs Enhances Drug Delivery with LipoDrive™ Platform
Creative Biolabs introduces the LipoDrive™ platform, a cutting-edge solution for liposomal drug delivery, addressing the growing demand for precision in biopharmaceutical formulations.
Kamada Reports Strong Q1 2025 Growth and Expands Plasma Business
Kamada Ltd. showcases significant first-quarter growth with a 17% increase in revenue and 54% rise in Adjusted EBITDA, alongside strategic expansions in its plasma business and international deals.
Creative Biolabs Advances Microbiome-Based Drug Development with Enhanced LBP Analytics
Creative Biolabs has introduced an advanced microbial service platform to streamline the development of microbiome-based drugs, addressing key challenges in strain characterization, contaminant detection, and formulation stability.
Creative Biolabs Advances Antibody Engineering with Innovative Glycosylation Technology
Creative Biolabs has developed a sophisticated analytical platform for monoclonal antibody glycan profiling, enhancing therapeutic antibody effectiveness through precise Fc region modifications. These technological improvements could significantly impact biopharmaceutical drug development.
Clene Inc. to Present at D. Boral Capital Global Conference in New York
Clene Inc., a late clinical-stage biopharmaceutical company developing neurological disease treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors an opportunity to learn about its innovative research and potential therapeutics.
Quantum BioPharma Strengthens Board with Anti-Corruption Financial Expert
Quantum BioPharma adds Kevin Malone, a seasoned financial advisor with extensive experience in market integrity and shareholder protection, to its Board of Directors as an advisor, signaling the company's commitment to transparent and ethical financial practices.
Quantum BioPharma Strengthens Board with Financial Integrity Expert Kevin Malone
Quantum BioPharma adds financial advisor Kevin Malone to its board, signaling a commitment to shareholder protection and transparency in the biopharmaceutical sector.
Kamada Expands Plasma Collection with New San Antonio Facility to Boost Therapeutic Capabilities
Kamada Ltd. is opening a third plasma collection site in San Antonio, Texas, aimed at increasing its specialty hyper-immune plasma production and potentially generating $8-10 million in annual revenue while reducing dependency on third-party suppliers.